Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells

被引:0
|
作者
Tahereh Hojjatipour
Zahra Sharifzadeh
Amirhosein Maali
Mehdi Azad
机构
[1] Tehran University of Medical Sciences,Department of Hematology and Blood Transfusion, Students Research Center, School of Allied Medicine
[2] Pasteur Institute of Iran,Department of Immunology
[3] Qazvin University of Medical Sciecnes,Department of Medical Biotechnology, Faculty of Allied Medicine
[4] Qazvin University of Medical Sciences,Department of Medical Laboratory Sciences, School of Paramedicine, Faculty of Allied Medicine
来源
Human Cell | 2023年 / 36卷
关键词
CAR-NK cells; Cancer immunotherapy; Chimeric antigen receptors; NK cell; Adoptive cellular therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Natural killer (NK) cells are a critical component of innate immunity, particularly in initial cancer recognition and inhibition of additional tumor growth or metastasis propagation. NK cells recognize transformed cells without prior sensitization via stimulatory receptors and rapidly eradicate them. However, the protective tumor microenvironment facilitates tumor escaping via induction of an exhaustion state in immune cells, including NK cells. Hence, genetic manipulation of NK cells for specific identification of tumor-associated antigens or a more robust response against tumor cells is a promising strategy for NK cells’ tumoricidal augmentation. Regarding the remarkable achievement of engineered CAR-T cells in treating hematologic malignancies, there is evolving interest in CAR-NK cell recruitment in cancer immunotherapy. Innate functionality of NK cells, higher safety, superior in vivo maintenance, and the off-the-shelf potential move CAR-NK-based therapy superior to CAR-T cells treatment. In this review, we have comprehensively discussed the recent genetic manipulations of CAR-NK cell manufacturing regarding different domains of CAR constructs and their following delivery systems into diverse sources of NK cells. Then highlight the preclinical and clinical investigations of CAR-NK cells and examine the current challenges and prospects as an optimistic remedy in cancer immunotherapy.
引用
收藏
页码:1843 / 1864
页数:21
相关论文
共 50 条
  • [31] Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
    Bauser, Maximilian
    Einsele, Hermann
    Loeffler, Juergen
    Hudecek, Michael
    Seif, Michelle
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2024, (212):
  • [32] Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
    Zhang, Jianguang
    Zheng, Huifang
    Diao, Yong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (02):
  • [33] Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy
    Temme, Achim
    Schmitz, Marc
    IMMUNOTHERAPY, 2016, 8 (09) : 983 - 986
  • [34] Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells
    Reighard, Seth D.
    Cranert, Stacey A.
    Rangel, Kelly M.
    Ali, Ayad
    Gyurova, Ivayla E.
    de la Cruz-Lynch, Arthur T.
    Tuazon, Jasmine A.
    Khodoun, Marat, V
    Kottyan, Leah C.
    Smith, David F.
    Brunner, Hermine, I
    Waggoner, Stephen N.
    CELL REPORTS MEDICINE, 2020, 1 (01)
  • [35] Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells
    Gurney, Mark
    O'Reilly, Eimear
    Corcoran, Sarah
    Brophy, Sarah
    Krawczyk, Janusz
    Otto, Neil M.
    Hermanson, David L.
    Childs, Richard W.
    Szegezdi, Eva
    O'Dwyer, Michael E.
    CYTOTHERAPY, 2022, 24 (11) : 1087 - 1094
  • [36] Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
    Cai Zhang
    Yuan Hu
    Weihua Xiao
    Zhigang Tian
    Cellular & Molecular Immunology, 2021, 18 : 2083 - 2100
  • [37] Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
    Zhang, Cai
    Hu, Yuan
    Xiao, Weihua
    Tian, Zhigang
    CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (09) : 2083 - 2100
  • [38] Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer
    Lee, Juheon
    Song, Jinhoo
    Yoo, Wonbeak
    Choi, Hyunji
    Jung, Dana
    Choi, Eunjeong
    Jo, Seo-Gyeong
    Gong, Eun-Yeung
    Jeoung, Young-Hee
    Park, You-Soo
    Son, Woo-Chang
    Lee, Hosuk
    Lee, Hayoung
    Kim, Jeom Ji
    Kim, Taeeun
    Lee, Sooyun
    Park, Jang-June
    Kim, Tae-Don
    Kim, Seok-Ho
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (02)
  • [39] Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
    Liu, Wai Nam
    So, Wing Yan
    Harden, Sarah L.
    Fong, Shin Yie
    Wong, Melissa Xin Yu
    Tan, Wilson Wei Sheng
    Tan, Sue Yee
    Ong, Jessica Kai Lin
    Rajarethinam, Ravisankar
    Liu, Min
    Cheng, Jia Ying
    Suteja, Lisda
    Yeong, Joe Poh Sheng
    Iyer, N. Gopalakrishna
    Lim, Darren Wan-Teck
    Chen, Qingfeng
    SCIENCE ADVANCES, 2022, 8 (47)
  • [40] Targeted Integration of a Chimeric Antigen Receptor in Key Selected Loci in Primary Natural Killer Cells
    Allain, Vincent
    Rothrock, Allison
    Nyberg, William
    Muldoon, Joseph
    To, Angela
    Chung, Jing-Yi
    Chang, Christopher
    Talbot, Alexis
    Eyquem, Justin
    BLOOD, 2023, 142